Kornimate/medical-research-clean huggingface dataset:
real world study of covid-19 in a flyover region

Conditions: Covid19

Summary: real world data are needed on remdesivir (rdv) efficacy in covid-19, especially in the underserved populations of the united states (u.s.) gulf coast as initial clinical trials may not be representative of this population. specifically, regions such as new orleans are 60% african american, a much greater proportion of african americans than initial rdv studies. the main hypothesis is that a real world data based study will provide specific information related to rdv efficacy in covid-19 patients from underserved / underrepresented populations of the u.s. gulf coast. the main goal of this study is to provide population-centered information related on rdv related to indication (stage of disease), dosing, monitoring, efficacy and contraindications for future covid-19 patients in this underserved region.

this study involves extracting data from 10,000 patients with polymerase chain reaction (qpcr) confirmed covid-19 infection through electronic-charts of tulane medical center and university medical center (new orleans, louisiana) and doctors hospital at renaissance (dhr) system (texas). according to the inclusion criteria below and spanning from september 2019 - december 2021 we predict to include 1500 rdv treated patients and 8500 non-treated comparators, all with covid-19, through the research action for health network (reachnet) (link: https://eco.reachnet.org) in partnership with the louisiana public health institute (lphi). statistical plan: following anonymized data extraction, propensity score will be used to compare primary and secondary endpoints between matched covid-19 infected patients who received rdv to those who did not receive rdv. patients of both cohorts will be stratified by severity. moderate and severe respiratory distress associated with covid-19 are defined as per us-gs-540-5773 and us-gs-540-5774 clinical trials. through the investigator's extensive electronic medical record (emr) data collection network including diverse underserved populations of the u.s. gulf south, they will evaluate real world outcomes of rdv treatment for covid-19. the 2 cohorts will be compared with focus upon respiratory distress evolution, co-morbidities and other illness associated/relevant to covid-19 course during admission, post-discharge during convalescent period of up to 6 months, and documentation of pre-admission comorbidities in the 6 months pre-admit.

Eligibility criteria:
inclusion criteria: * positive qrt pcr for covid-19 from a nasopharyngeal, nasal, or oropharyngeal swab or from bronchoalveolar lavage. * received rdv (cases) or did not receive rdv (controls). * age ≥ 18 years exclusion criteria: - none.

Keywords: remdesivir
effects of cannabidiol on burnout syndrome and empathy of caregivers of older adults

Conditions: Burnout Syndrome

Summary: burnout syndrome is an occupational disease that has affected health care providers, for example, caregivers of older adults. this syndrome negatively affects physical and psychological health, which may reflect on the mental health of the caregiver and the care provided to the older adults. interventions have been developed to minimize the impacts of burnout. thus, this study has two main objectives: 1) to identify the effect of cannabidiol on indicators of burnout and empathy of caregivers of older people with functional dependence for activities of daily living; 2) identify possible associations between burnout indicators, empathy levels and their domains, and quality of care. this is a two-phase study (i.e., phase 1: cross-sectional; phase 2: clinical trial). in phase 1, caregivers will answer questionnaires developed by researchers for sociodemographic characterization, care and satisfaction of care. in addition, they will complete instruments to assess the functional dependence of the older people - eiavd, depressive symptoms - phq-9, social support - eas, burnout syndrome - mbi and empathy - emri and met. in phase 2, caregivers will be randomized to cannabidiol or placebo intervention. caregivers with number 0 will be allocated to the intervention using cannabidiol (300mg - divided into two times a day) and those drawn with number 1 will be allocated to the placebo group. both interventions will be performed for four weeks. caregivers will fill in the mbi, emri, met, npi and qao instruments before and after the intervention. uku-sers will also be applied to evaluate side effects, iecc to assess the impact of intervention on care and cgi to assess severity and response to treatment.


Eligibility criteria:
inclusion criteria: * total score 4 in the ieavd * score on the emotional exhaustion subscale of mbi 9 and/or depersonalization 6 and/or; professional achievement 10 * low level of empathy in the emri scale (i.e., total score 71) * in addition, they should have a score of 10 on the phq-9, indicating absence of expressive depressive symptoms exclusion criteria: * not have the availability to participate in this phase of the research will be excluded * who have ceased to exercise the position of carer of a person aged 60 years or more * who no longer perform minimum workload of six hours daily and * not complete the protocol of the intervention received.

Keywords: cannabidiol caregivers empathy burnout syndrome
exalt: exercise attenuates liver tumors trial

Conditions: Hepatocellular Carcinoma

Summary: the overall goal of this proposal is to test the effect of exercise to delay or avert hcc recurrence and gain information regarding the potential molecular mechanisms of hcc tumor inhibition by exercise.

primary liver cancer is the leading cause of cancer worldwide. the majority of primary liver cancers are hepatocellular carcinoma (hcc) and occur in the setting of cirrhosis of the liver. body fat and systemic inflammation are determinants of hcc risk. cirrhotic patients with hcc are often treated with locoregional therapies including transarterial chemoembolization (tace) as a bridge to liver transplantation. despite this, hcc recurrence rates approach 80%. there is a growing body of evidence to suggest the benefit of exercise in cancer patients. exercise decreases disease recurrence and improves survival in other primary cancers by altering tumor biology and influencing response to treatment. although animal models suggest biologic plausibility, whether or not exercise prevents hcc recurrence in cancer patients remains unknown. the overall goal of this proposal is to test the effect of exercise to delay or avert hcc recurrence and gain information regarding the potential molecular mechanisms of hcc tumor inhibition by exercise.

Eligibility criteria:
inclusion criteria: * adults age \>=18 or \<70 years * liver transplant candidates (under evaluation or listed for transplant with hcc) * hepatocellular carcinoma diagnosis (hcc) * complete response to lrt exclusion criteria: * active cardiac symptoms * bmi \ 45 kg/m2(16) * cpt class b or c liver disease * ecog \>2 * hepatic decompensation * institutionalized/prisoner * pregnancy * severe medical comorbidities/psychiatric illness

Keywords: liver cancer
efficacy study of mpc-7869 to treat patients with alzheimer's

Conditions: Alzheimer Disease; Dementia

Summary: the purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with alzheimer's disease (ad) as measured by specific evaluations during 18 months of dosing.

this trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of mpc-7869 to placebo. the study subjects will have the diagnosis of mild dementia of the alzheimer's type. subjects may be taking approved medication for alzheimer's disease provided the dose has been stable for at least 6 months. the primary objective of the study is to evaluate the change in cognition and activities of daily living.

Eligibility criteria:
inclusion criteria: * have had a diagnosis of probable alzheimer's disease. * men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility). * signed the subject informed consent form and is willing and able to participate for the duration of the study. * ability to read and understand english or spanish to ensure compliance with cognitive testing and study visit procedures. * female subjects must be surgically sterile or postmenopausal for \> 1 year. * subjects currently taking approved medication for alzheimer's disease for at least six months prior to day 1 may be enrolled. * subjects must have a reliable caregiver who can read, understand and speak english or spanish. exclusion criteria: * current evidence of other causes of dementia. * history or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. men with prostate cancer may be enrolled at the discretion of the sponsor. * chronic or acute renal, hepatic or metabolic disorder. * use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of ad immunotherapy prior to screening. * major surgery and related complications not resolved within 12 weeks prior to day 1.

Keywords: alzheimer's dementia dementia of alzheimer type
efficacy, safety, and tolerability of eluxadoline in the treatment of participants with diarrhea-predominant irritable bowel syndrome (ibs-d)

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (jnj-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.


Eligibility criteria:
inclusion criteria: 1. participant is 18 to 80 years old 2. participant has a diagnosis of irritable bowel syndrome (ibs) with a subtype of diarrhea defined by the rome iii criteria. 2. participant has had a colonoscopy performed: * within 10 years prior to prescreening if participant is at least 50 years of age (sigmoidoscopy, double contrast barium enema, or computed tomography (ct) colonography within the past 5 years is acceptable) * since the onset (if applicable) of any of the following alarm features for participants of any age * participant has documented weight loss within the past 6 months * participant has nocturnal symptoms * participant has a familial history of first-degree relatives with colon cancer * participant has blood mixed with their stool (excluding blood from hemorrhoids). 3. female participants must be: * postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at prescreening, * surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), * abstinent, or * if sexually active, be practicing an effective method of birth control. exclusion criteria: 1. participant has a diagnosis of ibs with a subtype of constipation, mixed ibs, or unsubtyped ibs by the rome iii criteria. 2. participant has a history of inflammatory or immune-mediated gastrointestinal (gi) disorders including inflammatory bowel disease (ie, crohn's disease, ulcerative colitis) and celiac disease. 3. participant has a history of diverticulitis within 3 months prior to prescreening. 4. participant has a history of intestinal obstruction, stricture, toxic megacolon, gi perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease). 5. participant has any of the following surgical history: * cholecystectomy with any history of post cholecystectomy biliary tract pain * any abdominal surgery within the 3 months prior to prescreening * participant has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post surgery are allowed) other protocol-specific eligibility criteria may apply.

Keywords: irritable bowel syndrome with diarrhea irritable bowel syndrome diarrhea predominant irritable bowel syndrome colonic diseases colonic diseases, functional digestive system disease gastrointestinal disease intestinal disease colonic pseudo-obstruction diarrhea signs and symptoms, digestive
evaluation of left ventricular function after treatment of diabetic foot ulcers using longitudinal strain echocardiography

Conditions: Diabetic Foot Ulcers (DFU)

Summary: early detection of heart failure as a macrovascular complication of dm offers the best chance of cure in these patients. nowadays, the most common method for detecting heart failure is measuring left ventricle ejection fraction (lv-ef), by echocardiography. despite the easy application of lv-ef, it remains normal in early stages of cardiac disease and it's considered as heart failure with preserved lvef (hfpef). we hope that, strain monitoring as a new method enables us to detect the early minimal changes in myocardium. the aim of study evaluate the effect of treatment of diabetic foot ulcers in improving heart function by strain echocardiography than conventional transthoracic echocardiography in assiut university hospital.

diabetes mellitus (dm) is a chronic, metabolic disease with hyperglycemia that occurs as a result of deficiency or resistance of insulin hormone secreted from the pancreas. diabetic foot ulcer (dfu)is a frequent macrovascular complication has a high incidence and mortality rate. according to research statistics, the mortality rate of patients with foot ulcers after 5 years is 2.5 times higher than that of patients without such ulcers. heart failure develops in diabetic patients over twice higher than non-diabetics both directly, by impairing cardiac function, and indirectly, through associated diseases such as hypertension, coronary disease, renal dysfunction, obesity, and other metabolic disorders. based on a recent study, dfu treatment improves cardiac function assessed by strain measurements . at present, few data is available about the ability of strain echocardiography in prediction of systolic dysfunction in dfu, and the possible effect of the treatment of these patients on their cardiac function. so, we decided to evaluate the effect of treatment of diabetic foot ulcers in improving heart function by this new method-strain echocardiography.

Eligibility criteria:
inclusion criteria: * diabetic patients with dfu, who were diagnosed by a vascular surgeon based on diabetic foot study group guidelines. * diabetic patients were who used anti-diabetic oral medication, insulin or who had fasting blood glucose (fbs) ≥ 126 mg/dl for at least two times at age group 18 to 50 years at assiut university hospital exclusion criteria: * patients with acute or advanced stage of renal, hepatic or pulmonary diseases, acute coronary syndrome, known coronary artery disease ,infectious disease in the last two weeks, coagulopathy, history of a hemorrhagic stroke, severe valvular disease , heart failure (ef\<45%). * at age group below 18 or above 50 years old.
comparison of the effects of transcutaneous electrical nerve stimulation protocols in women with overactive bladder

Conditions: Overactive Bladder

Summary: the aim of our study is a comparison of the effects of transcutaneous electrical nerve stimulation (tens) protocols in women with overactive bladder (oab).

oab is a condition defined by the international continence society as the presence of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. tens has positive effects on oab. however, there are not enough studies on how often this stimulation is applied. studies are needed on this subject.

Eligibility criteria:
inclusion criteria: * being in the age range of 18-65 , * having diagnosed with oab, * being a volunteer exclusion criteria: * being pregnant, * presence of severe pelvic organ prolapse, * malignant disease, * urinary infection, * neurological disease, * have electronic and metal implant, * loss of sensation, * lumbosacral peripheral nerve lesion
methods of weight loss in overweight coronary patients

Conditions: Obesity

Summary: we hypothesize that a combination of high-caloric expenditure exercise and behavioral weight loss counseling would lead to a greater loss of fat mass and a greater improvement in cardiometabolic risk factors that standard (lower caloric expenditure) cardiac rehabilitation exercise plus counseling.

we hypothesize that a combination of high-caloric expenditure exercise and behavioral weight loss counseling would lead to a greater loss of fat mass and a greater improvement in cardiometabolic risk factors that standard (lower caloric expenditure) cardiac rehabilitation exercise plus counseling. the study population consists of overweight (bmi \>27) patients with established coronary heart disease. the exercise and counseling program was of 4 months duration with extended follow up at 1 year.

Eligibility criteria:
inclusion criteria: * coronary heart disease * bmi \> 27 * peak vo2 \> 14.4 ml/kg/min exclusion criteria: * presence of diabetes

Keywords: obesity coronary heart disease coronary risk factors weight loss exercise
blood loss and transfusion requirement in infants treated with tranexamic acid

Conditions: Craniosynostoses

Summary: the primary objective of this study is to investigate whether tranexamic acid (txa) reduces perioperative blood loss and transfusion requirement in infants undergoing craniosynostosis surgery.

blood loss during pediatric craniosynostosis surgery can be significant and this may be exacerbated by a dilutional coagulopathy. multimodal blood conservation strategies may limit allogeneic transfusions, although rcts are few and limited. it is essential to investigate these techniques to determine their potential to reduce allogeneic blood transfusions and their associated cost and morbidity. tranexamic acid (txa) is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator. the result is inhibition of fibrinolysis and clot degradation. recent studies in adults undergoing cardiac surgery demonstrated that people with different genotypes for the plasminogen activator inhibitor-1 (pai-1) gene may have varying degrees of bleeding. pai-1 inhibits the transformation of plasminogen to plasmin thereby decreasing plasmin-induced fibrinolysis. thus, pai-1 promotes clot stability and the pai-1 polymorphism will affect the degree of bleeding and response to txa during craniosynostosis surgery.

Eligibility criteria:
inclusion criteria: * infants aged 2 months to 2 years undergoing anterior cranial vault reconstruction exclusion criteria: * known bleeding disorder as this may increase the risk of bleeding * current antifibrinolytic therapy as these patients may bleed less * patient or family history of thromboembolic disease as there may be potential risk of thrombosis * use of nsaids within 5 days of surgery as this may increase the risk of bleeding * known allergy to txa * history of renal insufficiency as txa is renally excreted * acquired colour vision defects as one of the first signs of long term txa toxicity is colour vision disturbance.

Keywords: blood loss and transfusion craniosynostoses tranexamic acid children
antihypertensive response to losartan and genetic polymorphisms

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.


Eligibility criteria:
inclusion criteria: * both gender less than 60 years old, with mild-moderate hypertension (sbp greater than and dbp equal or greater than 90 mmhg, bp \< 180/110) * never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit * patient in therapeutic wash out for 6 months * patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases * women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method * bmi \< 30 for men and \< 28 for women exclusion criteria: * secondary or malignant hypertension, na \ 5,5 mmol/l, or \< 3,0 mmol/l * cardiac disease such as ischemic, hf, arrhythmia, cardiac surgery * pregnant, breast feeding * history of nephropathy, metabolic disease, liver disease * alcohol or drug abuse * history of angioedema * has a known hypersensibility to study drug(s)
intranasal dexmedetomidine in children undergoing adenotonsillectomy suffering from mild upper respiratory tract infection

Conditions: Dexmedetomidine; Adenotonsillectomy; Respiratory Tract Infections

Summary: the purpose of this study is to detect the efficacy of intranasal dexmedetomidine as a premedication to general anesthesia in pediatric patients with respiratory comorbidities undergoing adenotonsillectomy.

respiratory comorbidities are associated with an increased incidence of peri-operative respiratory adverse effects (prae). upper and lower respiratory infections, as well as asthma, are common in children who are scheduled for adenotonsillectomy. when compared to healthy children, children with respiratory ailments have a three-fold increase in praes.

Eligibility criteria:
inclusion criteria: 1. children with recent mild uri or asthma. 2. aged from 3 to 10 years 3. asa physical status ii, 4. undergoing adenotonsillectomy exclusion criteria: 1. parental refusal of participation 2. evidence of moderate to severe upper respiratory tract infection at time of presentation on the day of surgery 3. lower respiratory tract infection 4. congenital heart diseases 5. known hypersensitivity to specific anesthetic agent 6. liver or renal disease
evaluation of gingival biotypes of anterior teeth in adults with abnormal skeletal jaw relations

Conditions: Abnormal Jaw Relations

Summary: the aim of this study is to evaluate gingival biotypes and width of keratinized gingiva in the anterior region of adults with abnormal skeletal jaw relations.

this study will include consecutive adult patients seeking orthodontic treatment with skeletal class ii and class iii jaw relations based on clinical and cephalometric values. each group will be further divided according to their vertical skeletal pattern. gingival biotype will be determined -using the probe transparency method- into either thick or thin biotype for all anterior teeth in both jaws. width of keratinized gingiva will be measured from the muco-gingival junction to the free gingival margin in the middle of the crown of the maxillary and mandibular anterior teeth using a digital caliper with a sensitivity of 0.01 mm. statistical analysis will be applied to see the correlation between gingival biotypes , width of keratinized gingiva , and abnormal skeletal jaw relations.

Eligibility criteria:
inclusion criteria: 1. adult patients having an age range of 18 -30 years. 2. adults with skeletal class ii and class iii jaw relation 3. fair oral hygiene with absence of any active periodontal disease. 4. patients with full permanent dentition (with the exception of third molars) with acceptable alignment of teeth. 5. absence of systemic disease (medically free patients). exclusion criteria: 1. patients with extensive restorations on the anterior teeth. 2. subjects taking medication affecting the periodontal tissues 3. history of previous periodontal surgery or orthodontic treatment. 4. pregnant or lactating female patients 5. syndromic patients